Human papillomavirus vaccination uptake and factors related to uptake in a traditional desert city in the United Arab Emirates

International Journal of STD and AIDS

Volumn 22, Issue 7, 2011, Pages 400-404

  Al Nuaimi, N S ^a   Al Ghas, Y S ^a   Al Owais, A H ^a   Grivna, M ^a   Schneider, J ^a   Nagelkerke, N J ^a   Bernsen, R M ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Girls; HPV; Human papillomavirus; Muslim; Uptake; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; ATTITUDE TO ILLNESS; FEMALE; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HIGH SCHOOL STUDENT; HUMAN; INFECTION PREVENTION; KNOWLEDGE; NORMAL HUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED ARAB EMIRATES; VACCINATION;

ADOLESCENT; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUESTIONNAIRES; UNITED ARAB EMIRATES; VACCINATION; YOUNG ADULT;

EID: 79960199940     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009380     Document Type: Article

References (24)

1. Dillner J, Meijer CJ, von Krogh G, Horenblas S. Epidemiology of human papillomavirus infection. Scand J Urol Nephrol 2000;205 Suppl:194-200
2. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3
3. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines (2006). See http://www.cdc.gov/STD/hpv/STDFact-HPV-vaccine-hcp.htm#ref1 (last accessed 1 June 2011)
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9
5. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) study group. J Natl Cancer Inst 1995;87:796-802
6. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide. In: IARC Cancer Base No.5 Version 2.0. Lyon, France: IARC Press, 2004
7. International Agency for Research on Cancer (IARC). Handbooks of Cancer Prevention: Cervix Cancer Screening. Lyon, France: IARC Press, Vol. 10, 2005
8. Bosch FX, Castellsague ́ X, de Sanjose ́ S. HPV and cervical cancer: screening or vaccination? Br J Cancer 2008;98:15-21
9. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43
10. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70
11. Centers for Disease Control and Prevention (CDC). HPV Vaccine information for clinicians. 2008. See http://www.asccp.org/PracticeManagement/HPV/tabid/5822/Default.aspx (last accessed 1 June 2011)
12. Friederichs V, Cameron JC, Robertson C. Impact of adverse publicity on MMR vaccine uptake: a population based analysis of vaccine uptake records for one million children, born 1987-2004. Arch Dis Child 2006;91:465-8
13. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-41
14. Thomas TL. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health. Pediatr Nurs 2008;34:429-31
15. Katz ML, Reiter PL, Kluhsman BC, et al. Human papillomavirus (HPV) vaccine availability, recommendations, cost, and policies among health departments in seven Appalachian states. Vaccine 2009;27:3195-200
16. Health Authority Abu Dhabi. Health Statistics. Abu Dhabi: Health Authority Abu Dhabi, 2008
17. Wooldridge JM. Inverse probability weighted estimation for general missing data problems. J Econometrics 2007;141:1281-301
18. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:997-1001
19. Stretch R. Implementing a school-based HPV vaccination programme. Nurs Times 2008;104:30-3
20. Wong LP. Young multiethnic women's attitudes toward the HPV vaccine and HPV vaccination. Int J Gynaecol Obstet 2008;103:131-5
21. Gilman M, Gilman SL, Johns MM 3rd. Human papillomavirus, abstinence, and the other risks. Lancet 2009;373:1420-1
22. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 2003;14:300-6
23. Chan SS, Yan Ng BH, Lo WK, Cheung TH, Hung Chung TK. Adolescent girls' attitudes on human papillomavirus vaccination. J Pediatr Adolesc Gynecol 2009;22:85-90
24. Tozzi AE, Ravá L, Stat D, Pandolfi E, Marino MG, Ugazio AG. Attitudes towards HPV immunization of Italian mothers of adolescent girls and potential role of health professionals in the immunization program. Vaccine 2009;27:2625-9